Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
These revisions simplify the McDonald Criteria, preserve their diagnostic sensitivity and specificity, address their applicability across populations, and may allow earlier diagnosis and more uniform and widespread use.
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
New evidence and consensus now strengthen the role of these criteria in the multiple sclerosis diagnostic workup to demonstrate dissemination of lesions in time, to clarify the use of spinal cord lesions, and to simplify diagnosis of primary progressive disease.
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.
It is concluded that a four-parameter dichotomized MRI model including gadolinium-enhancement, juxtacortical, infratentorial and periventricular lesions best predicts conversion to clinically definite multiple sclerosis.
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
Differential diagnosis of suspected multiple sclerosis: a consensus approach
Background and objectives Diagnosis of multiple sclerosis (MS) requires exclusion of diseases that could better explain the clinical and paraclinical findings. A systematic process for exclusion of…
Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis
Resting state fMRI in Alzheimer's disease: beyond the default mode network
White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging
- M. Bozzali, A. Falini, M. Filippi
- Medicine, PsychologyJournal of neurology, neurosurgery, and…
- 1 June 2002
White matter changes in patients with Alzheimer's disease are likely to be secondary to wallerian degeneration of fibre tracts due to neuronal loss in cortical associative areas.
Placebo-controlled trial of oral laquinimod for multiple sclerosis.
- G. Comi, D. Jeffery, M. Filippi
- Medicine, PsychologyThe New England journal of medicine
- 14 March 2012
In this phase 3 study, oral laquinimod administered once daily slowed the progression of disability and reduced the rate of relapse in patients with relapsing-remitting multiple sclerosis.